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Abstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA 
approved as ﬁ  rst line chemotherapy for the treatment of hormone refractory metastatic prostate 
cancer. Recent data from two large randomized Phase III trials showed a survival advantage 
in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed 
the perceptions about utilization of chemotherapy for this devastating disease and introduced 
a new paradigm/standard of care treatment for this patient population. The management of 
elderly patients with metastatic prostate cancer is an important issue because according to data 
from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer 
Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to 
increase since people are living longer. In this paper we will review the results of trials evaluat-
ing docetaxel in hormone refractory prostate cancer and the implications of these trials as they 
relate to diagnosis and management of this disease in the elderly man.
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Introduction
Prostate cancer is a major heath issue which continues to rank as the number one most 
common malignancy among American men, with an estimated incidence of 218,890 
new cases expected to occur in 2007 (American Cancer Society 2007). More than 
65% of all prostate cancers will be diagnosed in men 65 years of age and older, with 
9% being 70 years of age or older (Jemel et al 2007).
Unfortunately, 22% of men diagnosed with prostate cancer will initially present 
with metastatic disease. Additionally, between the ages of 60 and 69, there is a 7% 
probability (1 in every 14) of men diagnosed with local or regional prostate cancer 
who will have disease that progresses to a metastatic state. In men 70 years of age 
and older there exists a 13.83% probability (1 in every 7) of developing metastatic 
disease (Jemel et al 2007). Hormonal therapy (ie, surgical or chemical castration) 
is the mainstay of treatment for patients with metastatic disease. While the initial 
response is quite favorable in most men (with improvement in pain, shrinkage of soft 
tissue metastases, and decreases in prostrate speciﬁ  c antigen) the median duration of 
response has been in the range of only 18–24 months.
Historically, very few avenues of treatment were available for hormone refractory 
prostate cancer. Chemotherapy offered marginal response rates and was quite toxic 
(Eisenberger et al 1988). In the 1990s, studies evaluating mitoxantrone plus predni-
sone demonstrated improvement in pain when compared with best supportive care. 
FDA approval of this treatment regimen for patients with hormone refractory prostate 
cancer was for the ﬁ  rst time based on palliative functional outcomes (Tannock et al 
1996; Kantoff et al 1999).
In the continued search for treatments for hormone refractory prostate cancer, 
anti-microtubular agents were studied. Estramustine phosphate (a nitrogen mustard Clinical Interventions in Aging 2007:2(4) 556
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derivative of estradiol-17 beta phosphate) was the ﬁ  rst of 
these agents. It is believed to combine hormonal effects 
with microtubular inhibition through microtubule associated 
proteins and has alkylating activity (Hudes et al 1992). This 
agent received FDA approval based on a response rate of 20%, 
however, its associated side effects, particularly severe nausea, 
vomiting and thromboembolic complications resulted in much 
reluctance in its use. In fact, Fossa and colleagues (Fossa et al 
1990) reported that all aspects of quality of life deteriorated 
during its use. Although estramustine phosphate as a single 
agent showed limited activity, combination treatment with 
docetaxel revealed possible synergistic effects. Several studies 
demonstrated superior response rates with the combination 
treatment as evidenced by decline in prostate speciﬁ  c antigen 
and decrease in soft tissue metastases; however, no signiﬁ  cant 
improvement in survival (Petrylak et al 1999; Savarese et al 
1999; Sinibaldi et al 2002; Petrylak et al 2004).
Within the past decade, many Phase II trials have been 
conducted to compare docetaxel based regimens with mitoxan-
trone plus prednisone in an attempt to demonstrate improve-
ment with respect to standard of care. In 2004, two large 
randomized Phase III studies showed a survival advantage in 
men receiving docetaxel based regimens (Retrylak et al 2004; 
Tannock et al 2004) without increased toxicity in the elderly. 
As a result, more men with prostate cancer who are elderly are 
being treated with docetaxel. This paper reviews the results of 
trials evaluating docetaxel-based regimens, characterizing the 
incidence and management issues in elderly men being treated 
for hormone refractory metastatic prostate cancer.
Deﬁ  ning the treatment needs 
of the elderly patient
Prostate cancer has a disproportionately higher incidence in 
elderly men. Albeit, the deﬁ  nition of “elderly” is arbitrary 
since aging is a very individualized process. For the purposes 
of this paper, we will refer to men 60 years of age and older 
as “elderly”. In elderly men with prostate cancer, treatment 
must often be tailored to the individual patient, as age-related 
physical changes such as confounding medical problems 
from co-morbid diseases, and cognitive deﬁ  cits may affect 
and complicate management (Balducci and Beghe 2001).
Attitudes of physicians to 
chemotherapy in the elderly patient
Since elderly men have historically had a shorter life expec-
tancy, chemotherapy treatment in elderly men has been quite 
controversial. Additionally, it is at this elderly age when 
they are less able to withstand disease and treatment related 
morbidity. The impact of relative beneﬁ  t from therapy versus 
potential risks (side effects) associated with therapy has been 
an issue. Effective treatment is one that results in longev-
ity, improved quality of life, and decreases anxiety over the 
uncertainties of living with cancer. Treatment goals would 
be to reduce pain, improve fatigue, and strengthen social 
relationships with family and friends. Until recently, only 
two chemotherapeutic agents were available. Estramustine 
phosphate at best offered only a 20% response rate. Palliation 
could be achieved only with mitoxantrone plus prednisone 
(Tannock et al 1996; Kantoff et al 1999).
Evidence supporting the use 
of docetaxel in elderly patients 
with prostate cancer
Docetaxel is now US FDA approved, in combination with 
prednisone for the ﬁ  rst line treatment of patients with meta-
static hormone refractory prostate cancer. Docetaxel is a semi-
synthetic taxane, microtubular inhibitor. It causes disruption 
of the microtubular network in cells that is necessary for 
mitotic and cellular functions. Docetaxel binds to free tubulin 
and allows for binding of tubulin into stable tubules, inhibiting 
their disassembly. Prevention of disassembly of the microtu-
bules results in the inhibition of mitosis and cell growth (Kaus 
et al 2003, Taxotere Prescribing Information [package insert] 
2006) Not only is docetaxel an effective microtubule stabi-
lizer, it also is highly effective at Bcl-2 inactivation. Bcl-2 is 
an anti-apoptotic protein necessary for cell growth. Disruption 
of the Bcl-2 cell survival signal results in cell death (Haldar 
et al 1997; Stein 1999; Kaus et al 2003).
The approval of docetaxel was based upon data from two 
large randomized Phase III trials (ie, TAX-327 and SWOG 
9916) both showing signiﬁ  cant improvement in overall 
survival compared with the previously referenced standard 
treatment (ie, mitoxantrone plus prednisone) (Petrylak et al 
2004; Tannock et al 2004).
TAX-327
In the TAX-327 study, Tannock and colleagues (Tannock 
et al 2004) evaluated 1006 men with metastatic hormone 
refractory prostate cancer randomly assigned to 1 of 3 
treatment arms: docetaxel 75 mg/m2 iv every 21 days plus 
prednisone 5 mg orally twice daily up to 10 cycles; docetaxel 
30 mg/m2 iv weekly 5 of every 6 weeks plus prednisone 5 mg 
orally twice daily, up to 5 cycles; or mitoxantrone 12 mg/m2 
iv every 21 days plus prednisone 5 mg orally twice daily, up 
to 10 cycles. Pre-medication with dexamethasone 8 mg orally 
was given at 12 hours, 3 hours, and 1 hour prior to docetaxel Clinical Interventions in Aging 2007:2(4) 557
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for those receiving the every-21-day dosing; dexamethasone 
8 mg orally was given just prior drug administration for 
those receiving the weekly docetaxel dosing. Anti-emetics 
were given according to each individual practice. The study 
was designed to detect a 33% difference in survival between 
the docetaxel-based regimens compared with the mitoxan-
trone regimen. The study was not adequately powered to 
compare directly the two docetaxel regimens with each other. 
The patient population included approximately 45% men 
with symptomatic bone pain, with 90% having bone metasta-
ses. A quarter also had soft tissue metastases. Median prostate 
speciﬁ  c antigen at baseline ranged from 108 to 123 ng/mL. 
All patients had received at least one prior hormonal treat-
ment. The reported median survival was 18.9 months in the 
group receiving docetaxel on the every-21-day schedule, 
17.4 months in the group receiving weekly docetaxel and 
16.5 months in the mitoxantrone group. The hazard ratio 
of death in the group that received docetaxel every 21 days 
compared with those who received mitoxantrone was 0.76 
(95% conﬁ  dence interval [CI] 0.62–0.94, p = 0.009). In the 
group receiving weekly docetaxel, the hazard ratio was 0.91 
(95% CI 0.75–1.11, p = 0.36). The every-21-day administra-
tion of docetaxel was associated with a survival beneﬁ  t but 
the weekly schedule was not. While a 2-month difference in 
median survival may not seem like very much, the hazard 
ratio of 20% is a better functional outcome of overall survival 
beneﬁ  t over time. This survival beneﬁ  t is similar to the results 
reported in studies of chemotherapy for other solid tumors, 
such as breast and lung cancer, which suggests that prostate 
cancer has the same favorable chemo-sensitivity. Improve-
ment in pain was achieved in 35%, 31% , and 22% of patients 
receiving docetaxel every 21 days, docetaxel weekly, and 
mitoxantrone every 21 days respectively. Toxicity in the 
every-21-day docetaxel was primarily myelosuppression. 
Weekly docetaxel was tolerated with minimal myelosuppres-
sion in patients age 65 years and older, including those with 
poor performance status (Balducci et al 2000). Although the 
efﬁ  cacy was better with the every-21-day schedule, treatment 
with weekly docetaxel is an option for elderly men diagnosed 
with hormone refractory prostate cancer. Quality of life as 
measured by the Functional Assessment of Cancer Therapy-
Prostate tool was similar in the docetaxel arms, both of which 
produced better scores compared with the group that received 
the mitoxantrone plus prednisone arm.
SWOG 9916
In the SWOG 9916 study, Petrylak and colleagues (Tannock 
et al 2004) evaluated 634 men with hormone refractory 
prostate cancer with 21 cycles of either estramustine phosphate 
280 mg 3 times a day orally, days 1–5, plus docetaxel 60–70 
mg intravenously day 2 plus dexamethasone 60 mg orally in 3 
divided doses prior to each docetaxel infusion. The compara-
tive arm included mitoxantrone 12–14 mg/m2 intravenously 
every 21 days plus prednisone 5 mg orally twice a day. This 
study was designed to detect a 33% difference in survival. 
Patient characteristics included 36% of men with symptomatic 
bone pain and median prostate speciﬁ  c antigen at baseline 
ranging between 84 and 90 ng/mL. Ninety percent of patients 
enrolled had bone metastases and a quarter of the patients also 
had soft tissue metastases. The median overall survival was 
17.5 months for the group of patients receiving the estramus-
tine phosphate plus docetaxel compared with 15.6 months 
for the group of patients that received the mitoxantrone plus 
prednisone. This was clinically signiﬁ  cant with the p value 
equal to 0.02. Prostate speciﬁ  c antigen declines were greater 
in the group receiving estramustine phosphate plus docetaxel 
group compared to the mitoxantrone plus prednisone (50% vs 
27%, p  0.001). This is important to note because decline in 
prostate speciﬁ  c antigen has been correlated with improved 
survival in men with hormone refractory prostate cancer. 
The median time to progression for the two groups was 6.3 
months and 3.2 months respectively. This is a 27% improve-
ment favoring the estramustine phosphate plus docetaxel arm 
(p  0.001). The safety and tolerability of each treatment arm 
was also evaluated. Grade 3 and 4 toxicity was more com-
mon in the group that received estramustine phosphate plus 
docetaxel and included neutropenia, nausea, vomiting and 
cardiovascular events, largely attributable to the estramustine 
phosphate. For the group that received the mitoxantrone plus 
prednisone, higher rates of gastrointestinal events (particularly 
diarrhea and vomiting), higher rates of hematologic events, and 
higher rates of peripheral vascular and cardiovascular toxicity 
(particularly deep vein thrombosis and myocardial infarction) 
were seen. Overall, the beneﬁ  ts resulting from the estramustine 
phosphate plus docetaxel treatment came at the cost of higher 
toxicity. There was no increase in treatment related deaths, 
nor was there an increase rate of discontinuation of treatment 
between the two arms. Similar quality of life outcomes were 
also reported for the two groups.
Other studies evaluating 
estramustine phosphate plus 
docetaxel
Kreis and Budman (1999), Savarese et al (1999), and 
Sinibaldi et al (2002) also evaluated the combination of Clinical Interventions in Aging 2007:2(4) 558
Sinibaldi
docetaxel plus estramustine. The median age of men was 
62 for the Phase II trial reported by Kreis and Budman, but 
all other trials including the phase I trial reported by Kreis 
and Budman, reported a median age greater than 65 years 
of age. While signiﬁ  cant prostate cancer speciﬁ  c antigen 
reductions were reported (82%, 69%, 45%) respectively, 
the combination was associated with an approximate 10% 
rate of thromboembolic complications. The thromboembolic 
complications were attributed to the estramustine. Based on 
this data and data from SWOG 9916, the future role of estra-
mustine phosphate in this stage of disease is questionable.
Studies evaluating single-agent 
docetaxel
As a single agent, docetaxel has been extensively evaluated. 
Picus and colleagues (Picus et al 1999) evaluated an 
every-3-week schedule at a dose of 75 mg/m2 given intra-
venously, with 46% achieving a prostate speciﬁ  c antigen 
decline of greater than 50%. Treatment was associated with 
grade 3 and grade 4 neutropenia in 46% of the patients. Other 
investigators (such as Berry et al 1999; Berry and Beer 2003; 
Beer et al 2003; Earhart 1999) evaluated a weekly schedule 
of docetaxel 36 mg/m2 administered intravenously weekly 
times 6 weeks followed by a 2-week rest period. Prostate spe-
ciﬁ  c antigen declines were 41% and 47%, respectively. The 
grade 3 and grade 4 neutropenia was less than 10% for both 
studies. While none of the studies speciﬁ  cally compared the 
tolerance of docetaxel in elderly as opposed to young men, 
most of the patients who entered the studies were elderly, 
and reportedly had good tolerance.
Toxicities associated with docetaxel 
as reported in the TAX327 
and other studies
Analyses of data from the TAX-327 showed no correlation 
between age and myelosuppression, the major dose-limiting 
toxicity of this therapy. Therefore, age should not be a con-
traindication for treatment with docetaxel. The TAX 327 trial 
did show that the every-21-day administration of docetaxel 
was associated with greater neutopenia compared with the 
weekly docetaxel schedule. The every-21-day docetaxel arm 
had patients with a median age of 68, range 42–92 years, 
with 20% of patients, equal or greater than 75 years of age. 
The weekly docetaxel schedule had patients with a median 
age of 69, range of 36–92 years, with 21% of patients 75 
years of age. The risk of neutropenia was more a potential 
toxicity, related to the schedule of docetaxel administration 
as opposed to age of the population, with an incidence of 
32% grade 3 and grade 4 neutropenia in the every-21-day 
docetaxel arm versus 2% incidence of grade 3 and grade 4 
neutropenia in the weekly docetaxel arm. The incidence of 
febrile neutropenia, and its potential complication of death 
was seen in only 3% of the every-21-day docetaxel dosing 
schedule, but not at all in the weekly schedule. Prophylaxis 
with colony stimulating factor (GMCSF), especially in men 
receiving the every-21-day docetaxel dosing schedule, should 
be considered in men greater than 65 years of age and is 
now listed in the National Comprehensive Cancer Network 
guidelines v.1 (2006). Docetaxel should be administered only 
when the absolute neutrophil count is 1500 cells/mm3. In 
patients who experience febrile neutropenia, with absolute 
granulocyte counts of less than 500 cells/mm3 for greater than 
1 week, severe skin reaction, or neurotoxicity, the dose of 
docetaxel should be decreased from 75 mg/m2 to 60 mg/m2, 
intravenously every 3 weeks. Treatment should be discontin-
ued if the patient continues to experience any recurrent life 
threatening or persistent morbidity. In the TAX 327 study, the 
incidence of grade 3 and grade 4 thrombocytopenia occurred 
in only 1% of patients receiving the every 21-day docetaxel 
dosing arm and not at all in the weekly schedule. Berry and 
Beer (2003) reported on the grade 3 hematologic toxicity of a 
weekly docetaxel schedule in men below and above the age of 
70 years ﬁ  nding no signiﬁ  cant difference in incidence (95% 
CI ). There was also no difference in overall hematologic and 
non-hematologic toxicity equal or greater than grade 2 in a 
comparison of pooled individual patient data from 2 Phase II 
studies of weekly docetaxel in androgen-dependent prostate 
cancer. The study also did not reveal signiﬁ  cant differences 
in efﬁ  cacy or toxicity in men aged over 70 years, compared 
with younger patients (Beer et al 2003).
The clearance of docetaxel is through hepatic metabolism. 
Caution should deﬁ  nitely be observed with administration 
in patients with hepatic dysfunction. Drug clearance is 
independent of renal function and appears to have no effect 
on nephrotoxicity. Clearance is independent of age (Earhart 
1999; Taxotere Prescribing Information [package insert] 
2006). Elderly patients may be more susceptible to mucositis, 
and diarrhea, but these adverse events were not statistically 
different in incidence based on dose schedule (Tannock et al 
2004; Goker and Rodenhuis 2005). Prompt treatment to 
prevent dehydration and failure of vascular support should 
be considered when administering docetaxel. Advanced age 
and associated co-morbidites such as diabetes may increase 
risk of peripheral and central neuropathy. Dose reductions 
are advised for severe sensory neuropathy, which occurred Clinical Interventions in Aging 2007:2(4) 559
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in 30% of the every-21-day docetaxel schedule and 24% of 
the weekly docetaxel schedule overall; but only 1.8% was 
grade 3 or grade 4 toxicity in the TAX-327 study (Tannock 
et al 2004). The TAX-327 study also reported nausea and 
vomiting in 42% of the patients receiving the every-21-day 
docetaxel schedule and 41% of the weekly docetaxel sched-
ule; however, grade 3 and grade 4 nausea was only 2.7% 
in the every-21-day docetaxel arm. Therefore, anti-emetic 
prophylaxis should be individualized as per one’s practice. 
Peripheral edema was seen in 19% in the every-21-day 
docetaxel schedule, and in 12% of the weekly docetaxel 
schedule (Tannock et al 2004). In order to potentially avoid 
reversible hypersensitivity reactions and ﬂ  uid retention, 
pretreatment steroids are highly recommended. Occurrences 
of these symptoms are signiﬁ  cantly decreased with pre-
medication of dexamethasome prior to docetaxel infusions. 
Although cardiotoxicity is another risk in the elderly, routine 
use of protective measures is unnecessary. Fatigue, hair 
thinning, and skin rashes are often more common with the 
every-21-day schedule. Nail changes are more common with 
the weekly schedule than with the every-21-day schedule 
(37% vs 30%, respectively) (Tannock et al 2004). Grade 3 
and grade 4 blockage of the lacrimal drainage apparatus 
causing excessive tearing occurred in 0.6% in the TAX 327 
study, but Esmaeli and colleagues reported this as a more 
common occurrence with the weekly schedule (Esmaeli et al 
2003). Excessive eye tearing should be monitored and prompt 
intervention is imperative.
Of the 333 patients treated with docetaxel plus pred-
nisone every 3 weeks in the TAX 327 study, 63% (209 
patients) were equal or greater than 65 years of age, and 
20% (68 patients )were equal or greater than 75 years of age. 
Adverse events (all grades) that occurred at rates equal or 
greater than 10% in patients 65 years of age or older versus 
younger patients included: anemia (71% vs 59%), infec-
tion (37% vs 24%), nail changes (34% vs 23%), anorexia 
(21% vs 10%), and weight loss (15% vs 5%) (Haldar et al 
1997).
Docetaxel as upfront therapy 
or second-line therapy
Docetaxel has shown efﬁ  cacy when given up front or as sec-
ond-line therapy. The optimal duration of therapy is not known. 
The TAX-327 study showed improved patient outcomes in 
the groups of patients that received docetaxel plus prednisone 
compared with the group that received mitoxantrone plus pred-
nisone. Small pilot studies suggest that intermittent therapy is 
feasible and may reduce toxicity in a small subset of patients.
Conclusions
As our population ages, the number of elderly patients with 
prostate cancer is expected to increase. Studies have shown 
that elderly patients may beneﬁ  t from chemotherapy to the 
same extent as younger patients. Age-related factors such as 
social, functional, and cognitive impairment may compli-
cate management. The safety, efﬁ  cacy, and convenience of 
therapy should be optimized. The decision to proceed with 
chemotherapy treatment relies upon a careful assessment 
of the patient’s co-morbidities and functional status, and a 
thorough discussion of the risks and beneﬁ  ts of treatment. 
Mitoxantrone plus prednisone was previously accepted as 
standard chemotherapy for this stage of disease; however, 
docetaxel-based regimens have been shown to both palli-
ate symptoms and prolong survival in hormone refractory 
prostate cancer. Docetaxel is now universally accepted as the 
best available chemotherapy for prostate cancer progressing 
on hormonal therapy.
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